Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard ...

Eight-month-old Rowan Edgell was diagnosed with a rare type of infantile fibrosarcoma at only a few months old. After several ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of interim data from ...

Discover IMRX’s innovative cancer drug atebimetinib and upcoming milestones. Learn about trial results, financial outlook, ...

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...

Burkitt's lymphoma is a highly aggressive blood cancer that primarily affects children and young adults. It is driven by a ...

Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will host a conference call and ...

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.

For decades, Iranians have confronted one of the world’s most entrenched authoritarian systems with little more than resilience and collective resolve. Iran’s future cannot be negotiated without the ...